NEW YORK - Hoth Therapeutics, Inc. (NASDAQ: HOTH), a micro-cap biotech company with a market capitalization of $10.2 million, has obtained a new patent from the Japan Patent Office, reinforcing its ...
CRISPR gene editing has transitioned from a laboratory curiosity to a cornerstone of modern biotechnology, revolutionizing our approach to genetic diseases, including Charcot-Marie-Tooth (CMT) disease ...
HT-KIT demonstrates significant tumor downregulation and over 80% reduction in KIT expression in preclinical models of GIST and systemic mastocytosis. The therapy targets KIT gene expression at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results